Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10637/10086
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.otherProducción Científica UCH 2018-
dc.contributor.otherUCH. Departamento de Ciencias Biomédicas-
dc.contributor.otherUCH. Departamento de Cirugía (Extinguido)-
dc.contributor.otherUCH. Departamento de Medicina y Cirugía-
dc.creatorMérida Donoso, Salvadores
dc.creatorSancho Tello, Maríaes
dc.creatorAlmansa Frías, María Inmaculadaes
dc.creatorDesco Esteban, Ma. Carmenes
dc.creatorPeris Martínez, Cristinaes
dc.creatorMoreno, María Luzes
dc.creatorVillar Amigó, Vicentees
dc.creatorNavea Tejerina, Amparoes
dc.creatorBosch Morell, Francisco-
dc.date2018es
dc.date.accessioned2019-03-07T05:00:41Z-
dc.date.available2019-03-07T05:00:41Z-
dc.date.issued2018-06-07-
dc.identifier.citationMérida, S., Sancho-Tello, M., Almansa, I., Desco, C., Peris, C., Moreno, ML., Villar, VM., Navea, A. and Bosch-Morell, F. (2018). Bevacizumab diminishes inflammation in an acute endotoxin-induced uveitis model. Frontiers in Pharmacology, vol. 9, art. 649. DOI: https://doi.org/10.3389/fphar.2018.00649-
dc.identifier.issn1663-9812.-
dc.identifier.urihttp://hdl.handle.net/10637/10086-
dc.descriptionEste artículo se encuentra disponible en la página web de la revista en la siguiente URL: https://www.frontiersin.org/articles/10.3389/fphar.2018.00649/fulles
dc.description.abstractIntroduction: Uveitis is an eye disease characterized by inflammation of the uvea and an early and exhaustive diagnosis is essential for its treatment. The aim of our study is to assess the potential toxicity and anti-inflammatory efficacy of Bevacizumab in an experimental uveitis model by subcutaneously injecting lipopolysaccharide into Lewis rats and to clarify its mechanism. Material and Methods: Blood–aqueous barrier integrity was assessed 24 h after endotoxin-induced uveitis (EIU) by analyzing two parameters: cell count and protein concentration in aqueous humors. Histopathology of all eye structures was also studied. Enzyme-linked immunosorbent analyses of the aqueous humor samples were performed in order to calculate the diverse chemokine and cytokine protein levels and oxidative stress-related markers were also evaluated. Results: The aqueous humor’s cellular content significantly increased in the group treated with only Bevacizumab, but it had no effect on retina histopathological grading. Nevertheless, the inflammation noted in ocular structures when administering Bevacizumab with endotoxin was mostly prevented since aqueous humor cell content considerably lowered, and concomitantly with a sharp drop in uveal, vitreous, and retina histopathological grading. The values of the multi-faceted cytokine IL-2 also significantly decreased (p < 0.05 vs. endotoxin group), and the protective IL-6 and IL-10 cytokines values rose with related anti-oxidant system recovery (p < 0.05 vs. endotoxin group). Concurrently, some related M1 macrophage chemokines substantially increased, e.g., GRO/KC, a chemokine that also displays any kind of protective role. Conclusion: All these results revealed that 24 h after being administered, Bevacizumab treatment in EIU significantly prevented inflammation in various eye structures and correct results in efficacy vs. toxicity balance were obtained.-
dc.formatapplication/pdfes
dc.language.isoenes
dc.publisherFrontiers Media-
dc.relationEste estudio fue financiado por la Fundación CEU Santander con la beca PRCEU-UCH CON-15/05 e INDI16/04.-
dc.relationUCH. Financiación Universidad.-
dc.relation.ispartofFrontiers in Pharmacology, vol. 9 (june 2018)-
dc.rightshttp://creativecommons.org/licenses/by/4.0/deed.eses
dc.subjectUveítis - Tratamiento.es
dc.subjectOjos - Enfermedades - Tratamiento.es
dc.subjectBevacizumab - Efectos fisiológicos.es
dc.subjectÚvea - Efectos de los medicamentos.es
dc.subjectBevacizumab - Physiological effect.es
dc.subjectUveitis - Treatment.es
dc.subjectEstrés oxidativo.es
dc.subjectFarmacología.es
dc.subjectPharmacology.es
dc.subjectBevacizumab - Efectos secundarios.es
dc.subjectOxidative stress.es
dc.subjectUvea - Effect of drugs on.es
dc.subjectBevacizumab - Side effects.es
dc.subjectEyes - Diseases - Treatment.es
dc.titleBevacizumab diminishes inflammation in an acute endotoxin-induced uveitis modeles
dc.typeArtículoes
europeana.dataProviderUNIVERSIDAD SAN PABLO CEU-
europeana.isShownAthttp://hdl.handle.net/10637/10086-
europeana.objecthttp://repositorioinstitucional.ceu.es/visor/libros/707854/thumb_europeana/707854.jpg-
europeana.providerHispana-
europeana.rightshttp://creativecommons.org/publicdomain/zero/1.0/-
europeana.typeTEXT-
dc.identifier.doihttps://doi.org/10.3389/fphar.2018.00649-
dc.relation.projectIDPRCEU-UCH CON-15/05-
dc.relation.projectIDINDI16/04-
dc.centroUniversidad Cardenal Herrera-CEU-
Aparece en las colecciones: Dpto. Farmacia




Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.